Difference between revisions of "Profiles"
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles=== | ||
| − | *[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | | + | *[[Media:MRE-QIBAProfile-2018-05-02-CONSENSUS.pdf | MR Elastography of the Liver 2018-05-02]] |
| + | |||
| + | * [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.02.11.docx|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-02-11]] | ||
| + | |||
| + | *[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Quantifying Dopamine Transporters with 123 - Iodine Labeled Ioflupane in Neurodegenerative Disease v1.1 2017-06-26]] | ||
| − | |||
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | :*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]] | ||
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]] | * [[Media:QIBA_CTVol_TumorVolumeChangeProfile_Consensus-20161121b.pdf| CT Tumor Volumetry for Advanced Disease 2016-11-21b]] | ||
| + | |||
:* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]] | :* [[Media:QIBA_CVol_TumorVolumeChangeChecklist-20161205_-_Field_Test_version_1.0.docx| Checklist - CT Tumor Volumetry for Advanced Disease]] | ||
| − | |||
| − | |||
| − | *[[Media:DCE-MRI Quantification Profile v1.0.pdf| | + | *[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]] |
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
Revision as of 19:57, 18 May 2018
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Stage 3: Technically Confirmed Profiles
Stage 2: Consensus Profiles
Stage 1: Public Comment Profiles
Submit comments using the online form: http://tinyurl.com/QIBA-Public-Comment-Form
(Note: each form accommodates 10 comments; submit additional forms as necessary)
- There are currently no Profiles open for Public Comment
Public Comment closed for the following Profiles (comment resolution is currently underway):
- QIBA fMRI Profile 2017-06-19 (Closed on December 31, 2017)
- QIBA PET Amyloid Profile: 18F-labeled PET Tracers Targeting Amyloid as an Imaging Biomarker - 2018-05-02 (Closed on September 15, 2017)
- QIBA MRE Profile 2017-08-15 (Closed on September 15, 2017)
- DWI Profile 2017-04-27 (Closed on August 25, 2017)
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. * Specific Profile Title, * Quantitative Imaging Biomarkers Alliance. * Version. * Profile Stage. * QIBA, * Date. * Available from: URL
Example:
- QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)